Eton Pharmaceuticals, Inc. (ETON) 追踪市盈率为负值 -154.5, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 32.7 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -0.65%, 前瞻盈利收益率 3.06%. PEG 0.52 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 38/100 其中 1/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2017 | -15.2 | 0.00 | 9.00 | 0.00 | - |
| 2018 | -3.1 | -0.01 | 1.49 | 0.00 | 2.67% |
| 2019 | -7.0 | 0.14 | 12.12 | 133.34 | - |
| 2020 | -6.1 | -0.20 | 10.91 | 4,379.78 | - |
| 2021 | -55.3 | 0.59 | 6.13 | 4.95 | - |
| 2022 | -7.9 | -0.02 | 5.42 | 3.34 | - |
| 2023 | -120.0 | 1.34 | 7.26 | 3.55 | - |
| 2024 | -90.2 | -0.29 | 14.12 | 8.84 | - |
| 2025 | -98.9 | -7.42 | 17.40 | 5.69 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2017 | $-0.41 | $0.00 | $-7.16M | - |
| 2018 | $-1.99 | $0.00 | $-12.74M | - |
| 2019 | $-1.02 | $959K | $-18.04M | -1881% |
| 2020 | $-1.37 | $39K | $-28.83M | -73920.5% |
| 2021 | $-0.12 | $21.83M | $-2.96M | -13.6% |
| 2022 | $-0.39 | $21.25M | $-9.78M | -46% |
| 2023 | $-0.04 | $31.64M | $-936K | -3% |
| 2024 | $-0.15 | $39.01M | $-3.82M | -9.8% |
| 2025 | $-0.17 | $79.95M | $-4.6M | -5.8% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $0.83 | $0.60 – $1.05 | $110.44M | $110.35M – $110.52M | 2 |
| 2027 | $1.74 | $1.46 – $2.00 | $162.6M | $154.69M – $170.51M | 2 |
| 2028 | $2.68 | $2.02 – $3.42 | $221.77M | $221.77M – $221.77M | 3 |
| 2029 | $4.36 | $4.15 – $4.59 | $319.11M | $307.36M – $332.15M | 1 |
| 2030 | $5.87 | $5.58 – $6.18 | $405.98M | $391.04M – $422.56M | 1 |
